Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats

Diabetes

Volumn 52, Issue 3, 2003, Pages 741-750

  Pospisilik, J Andrew ^a   Martin, Jennifer ^a   Doty, Timothy ^a   Ehses, Jan A ^a   Pamir, Nathalie ^a   Lynn, Francis C ^a   Piteau, Shalea ^a   Demuth, Hans Ulrich ^b   McIntosh, Christopher H S ^a   Pederson, Raymond A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b PROBIODRUG AG   (Germany)

Author keywords

DP IV, dipeptidyl peptidase IV; GIP, glucose dependent insulinotropic polypeptide; GLP 1, glucagon like peptide 1; IDGTT, intraduodenal glucose tolerance test; IR, immunoreactive; OGTT, oral glucose tolerance test; PDX 1, pancreatic duodenum homeobox 1

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; PEPTIDE DERIVATIVE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL PROTECTION; CELL REGENERATION; CELL SURVIVAL; CONTROLLED STUDY; DIABETES MELLITUS; DIETARY INTAKE; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN SYNTHESIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS PERFUSION; PANCREAS SECRETION; PRIORITY JOURNAL; RAT; WEIGHT GAIN;

ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; CELL COUNT; CELL DIFFERENTIATION; CELL DIVISION; CELL SURVIVAL; DIABETES MELLITUS, EXPERIMENTAL; EATING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; GLUCOSE TOLERANCE TEST; IMMUNOHISTOCHEMISTRY; INSULIN; ISLETS OF LANGERHANS; LIPIDS; LIVER; MALE; PEPTIDE FRAGMENTS; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PROTEASE INHIBITORS; PROTEIN PRECURSORS; RATS; RATS, WISTAR; WEIGHT GAIN;

EID: 0037342614     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.3.741     Document Type: Article

References (39)

1. Atkinson M, Eisenbarth G: Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358:221-229, 2001
2. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, Tsuda K, Hashimoto H, Yamashita T, Jomori T, Tashiro F, Miyazaki J, Seino Y: Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci U S A 96:14843-14847, 1999
3. Pederson RA, Satkunarajah M, McIntosh CH, Scrocchi LA, Flamez D, Schuit F, Druker DJ, Wheeler MB: Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. Diabetes 47:1046-1052, 1998
4. Kieffer TJ, Habener JF: The glucagon-like peptides. Endocr Rev 20:876-913, 1999
5. Trumper A, Trumper K, Trusheim H, Arnold R, Goke B, Horsch D: Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 15:1559-1570, 2001
6. Xu G, Stoffers DA, Habener JF, Bonner-Weir S: Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276, 1999
7. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, Egan JM: Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49:741-748, 2000
8. Hui H, Wright C, Perfetti R: Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulinsecreting cells. Diabetes 50:785-796, 2001
9. Buteau J, Roduit R, Susini S, Prentki M: Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 42:856-864, 1999
10. Dachicourt N, Serradas P, Giroix MH, Gangnerau MN, Portha B: Decreased glucose-induced cAMP and insulin release in islets of diabetic rats: reversal by IBMX, glucagon, GIP. Am J Physiol 27I:E725-E732, 1996
11. Holz GG 4th, Kuhtreiber WM, Habener JF: Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 361:362-365, 1993
12. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835, 1993
13. Kieffer TJ, McIntosh CH, Pederson RA: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596, 1995
14. Pauly RP, Rosche F, Wermann M, McIntosh CH, Pederson RA, Demuth HU: Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptid 1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach. J Biol Chem 271:23222-23229, 1999
15. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ: Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575-3581, 2000
16. Hansen L, Deacon CF, Orskov C, Holst JJ: Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140:5356-5363, 1999
17. Pauly RP, Demuth HU, Rosche F, Schmidt J, White HA, Lynn F, McIntosh CH, Pederson RA: Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. Metabolism 48:385-389, 1999
18. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU: Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47:1253-1258, 1998
19. Pospisilik J, Stafford S, Demuth H-U, Brownsey R, Parkhouse W, Finegood D, McIntosh C, Pederson R: Long-term treatment with the DP IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia and β-cell glucose responsiveness in VDF (fa/fa) Zucker Rats. Diabetes 51:943-950, 2002
20. Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson P-A, Sandqvist M, Bavenholm P, Efendic S, Eriksson J, Dickinson S, Holmes D: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25:869-875, 2002
21. Sudre B, Broqua P, White R, Ashworth D, Evans D, Haigh R, Junien J-L, Aubert M: Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker Diabetic Fatty rats. Diabetes 51:1461-1469, 2002
22. Reimer MK, Holst JJ, Ahren B: Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 146:717-727, 2002
23. Pospisilik JA, Stafford SG, Demuth HU, McIntosh CH, Pederson RA: Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes 51:2677 2683, 2002
24. Demuth HU: Recent developments in inhibiting cysteine and serine proteases. J Enzyme Inhib 3:249-278, 1990
25. Jia X, Elliott R, Kwok YN, Pederson RA, McIntosh CH: Altered glucose dependence of glucagon-like peptide 1(7-36)-induced insulin secretion from the Zucker (fa/fa) rat pancreas. Diabetes 44:495-500, 1995
26. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322, 1992
27. Dupre J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P, McDonald TJ: Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 44:626-630, 1995
28. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA: Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1(7-36) amide in type I diabetic patients. Diabetes Care 19:580-586, 1996
29. Perfetti R, Zhou J, Doyle ME, Egan JM: Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 141:4600-4605, 2000
30. Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B: Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocintreated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50:1562-1570, 2001
31. Fernandes A, King LC, Guz Y, Stein R, Wright CV, Teitelman G: Differentiation of new insulin-producing cells is induced by injury in adult pancreatic islets. Endocrinology 138:1750-1762, 1997
32. Guz Y, Nasir I, Teitelman G: Regeneration of pancreatic beta cells from intra-islet precursor cells in an experimental model of diabetes. Endocrinology 142:4956-4968, 2001
33. Mentlein R: Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides. Regul Pept 85:9-24, 1999
34. Pospisilik JA, Hinke SA, Pederson RA. Hoffmann T, Rosche F, Schlenzig D, Glund K, Heiser U, McIntosh CH, Demuth H: Metabolism of glucagon by dipeptidyl peptidase IV (CD26). Regul Pept 96:133-141, 2001
35. Lambeir A-M, Durinx C, Proost P, Van Damme J, Scharpe S, De Meester I: Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in insulin secretion. FEBS Let 507:327-330, 2001
36. Inagaki N, Kuromi H, Seino S: PACAP/VIP receptors in pancreatic betacells: their roles in insulin secretion. Ann N Y Acad Sci 805:44-51; discussion 52-53, 1996
37. Jamen F, Persson K, Bertrand G, Rodriguez-Henche N, Puech R, Bockaert J, Ahren B, Brabet P: PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. J Clin Invet 105:1307-1315, 2000
38. Ahren B: Autonomic regulation of islet hormone secretion: implications for health and disease. Diabetologia 43:393-410, 2000
39. De Meester I, Korom S, Van Damme J, Scharpe S: CD26, let it cut or cut it down. Immunol Today 20:367-375, 1999